Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its drug candidate SAT-3247 for the treatment of Duchenne Muscular Dystrophy. This designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill unmet medical needs. Satellos Bioscience Inc. is a biotechnology company focused on developing therapies for neuromuscular diseases.

Satellos Bioscience Inc. filed a 6-K report of voting results for the month of June 2026. The filing contains no material governance-related changes or contested votes. Satellos Bioscience Inc. is a life sciences company.